Journal article
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience
Abstract
INTRODUCTION: Clinical trial data has shown pazopanib to be non-inferior in overall survival (OS) compared to sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC). The purpose of this study was to evaluate outcomes and compare dose-modifying toxicities of mRCC patients treated with suntinib or pazopanib in the real-world setting.
METHODS: Data were collected on mRCC patients using the prospective Canadian Kidney Cancer …
Authors
Lalani A-KA; Li H; Heng DYC; Wood L; Kalirai A; Bjarnason GA; Sim H-W; Kollmannsberger CK; Kapoor A; Hotte SJ
Journal
Canadian Urological Association Journal, Vol. 11, No. 3-4, pp. 112–117
Publisher
Canadian Urological Association Journal
Publication Date
2017
DOI
10.5489/cuaj.4398
ISSN
1911-6470